Other

Swiss pharma Novartis ups full-year sales outlook (Update)

Swiss pharmaceutical giant Novartis AG raised its full-year sales outlook because of delays in generic competition to its blockbuster blood pressure drug Diovan, even though it said negative currency trends contributed to ...

Other

German drug maker Merck ups forecast for 2013

German chemicals and pharmaceuticals giant Merck KGaA said Thursday it is raising its full-year operating profit forecast thanks to improving sales and positive cost-cutting effects.

Vaccination

AstraZeneca says Covid vaccine sales top $1.0 bn

British pharmaceuticals giant AstraZeneca said Thursday that its COVID jab generated $1.2 billion (1.0 billion euros) in sales in the first half of the year as global vaccination programmes accelerated.

Other

Novartis Q4 net profit rebounds to $2.1 billion

(AP)—Swiss drug maker Novartis AG reported a jump in fourth-quarter net profit to $2.08 billion on Wednesday, citing the lack of a $900-million one-time charge it took in the same period the previous year.

Other

Novartis Q4 net profit rises to $2.0 billion

Swiss drug maker Novartis AG reported a 2 percent rise in fourth-quarter net profit Wednesday, helped by delays in generic competition to its blockbuster drugs.

Other

Amgen 3Q profit jumps 24 pct. on stronger sales

Biotech drugmaker Amgen Inc. said Tuesday that its third-quarter profit jumped 24 percent, trouncing analysts' expectations, as sales of more than a half-dozen of its drugs increased by double digits.

page 4 from 5